PF-Atlas › Clinical Trials › NCT04905693

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Inhaled Treprostinil · Phase 3

Registry ID
NCT04905693
Phase
Phase 3
Status
Enrolling by invitation
Drug / intervention
Inhaled Treprostinil
Sponsor
United Therapeutics
Start
2022-09-06

About this trial

Inhaled Treprostinil is evaluated in NCT04905693, a Phase 3 idiopathic pulmonary fibrosis study sponsored by United Therapeutics. Current status: Enrolling by invitation.

View NCT04905693 on ClinicalTrials.gov →

Explore related

Inhaled Treprostinil / Tyvaso — Treatment profileAll Inhaled Treprostinil trialsAll IPF trials

Related trials

Inhaled Treprostinil — TETON-1Inhaled Treprostinil — TETON-2
Medical disclaimer. This page summarizes public trial data for NCT04905693 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.